SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4479)8/15/2001 2:55:57 PM
From: Michael Young  Respond to of 52153
 
Frankly I'm not concerned if the story was crafted by the shorts. The street is entirely geared to hyping these stocks, so I like to know what the shorts are thinking. They typically prey on the weakest stocks in a sector and smoke very often leads to fire.

MIKE



To: Biomaven who wrote (4479)8/15/2001 3:40:09 PM
From: Ian@SI  Read Replies (1) | Respond to of 52153
 
Peter,

Does it make any difference whether the source was from "shorts" or someone / something else? If there's a risk of kidney failure from BPUR's product, what doctor is going to abandon the existing product which doesn't have that safety issue.

With the rough time that the FDA is giving HMSL on its product (derived from human blood as opposed to BPUR using a bovine source), I'd be very surprised to see BPUR get any slack whatsoever.

FWIW,
Ian


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News